GERON CORP (GERN)       3.295  0 (-0.15%)

3.295  0 (-0.15%)

US3741631036 - Common Stock

GERON CORP3.295

NASDAQ:GERN (2/1/2023, 10:34:03 AM)0 (-0.15%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/bmo Earnings (Next) 03-08 2023-03-08
Ins Owners 0.13% Inst Owners 43.24%
Market Cap 1.44B Shares 437.11M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.67
IPO 07-31 1996-07-31

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GERN Daily chart

Company Profile

Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 69 full-time employees. The firm operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.

Company Info

GERON CORP

919 East Hillsdale Boulevard, Suite 250

Foster City CALIFORNIA 94404

P: 16504737700.0

CEO: John A. Scarlett

Employees: 69

Website: https://www.geron.com/

GERN News

News Image8 days ago - InvestorPlace7 A-Rated Stocks to Buy for Less Than $25

These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.

News Image9 days ago - Market News VideoFirst Week of September 15th Options Trading For GeronNews Image13 days ago - Geron CorporationGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)News Image20 days ago - Geron CorporationGeron to Present at the B. Riley Securities 3rd Annual Virtual Oncology ConferenceNews Image21 days ago - Seeking AlphaGERN stock sets commercial leadership for imetelstat launch (NASDAQ:GERN)

Geron Corporation (GERN) announced new additions to its senior commercial leadership on Wednesday ahead of the planned launch of blood cancer therapy imetelstat. Read the full story here.

News Image21 days ago - Geron CorporationGeron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.

GERN Twits

Here you can normally see the latest stock twits on GERN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example